Efficacy and Safety of Two Pharmacologic Strategies on Neurocognitive Impairment in HIV Infection. The TRIANT-TE Study
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
The current project proposes the comparison of two pharmacologic strategies as adjunctive
treatments for the improvement of HIV-associated neurocognitive disruption, additionally to
use of HAART. The investigators propose the use of the compound that has shown greatest
benefits in this context to date, the lithium, versus the use of a well-tolerated and
promising drug in other pathologies with neurocognitive affectation, such as Alzheimer or
Parkinson diseases, which is the rivastigmine. In those other diseases, this second compound
has recently offered a good tolerability, but also benefits on attention, memory and other
neurocognitive areas. Both study groups, patients on therapy with lithium and patients on
therapy with rivastigmine, will be compared to a control group, which will not initiate any
other treatment (therefore only continuing antiretroviral therapy). The investigators are
aware that this proposal will offer new relevant data for the study of neurocognitive
improvement in HIV infection, as well will allow a better knowledge of clinical management of
HIV-infected patients with CNS disease, an aspect that is a common clinical concern today.
Phase:
Phase 4
Details
Lead Sponsor:
Fundacio Lluita Contra la SIDA Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia